Skip to main content
Premium Trial:

Request an Annual Quote

Oxford Nanopore Technologies: John O'Higgins, Clive Brown

John O'Higgins and Clive Brown have joined the board of directors of Oxford Nanopore Technologies, the company said this week. According to a regulatory filing, the appointments were made last September. Brown is the company's chief technology officer. O'Higgins, who joined the board as a non-executive director, is the former CEO of Spectris, an instrumentation and controls company. He holds non-executive roles at several other companies and is a member of the corporate advisory board of Great Ormond Street Hospital Charity in the UK.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.